Tingsn and GE Healthcare Forge Strategic Alliance to Advance Intracardiac Echocardiography

Nov 08, 2024 17:58 CST Updated 17:59

TINGSN

Developer of Cardiac Interventional Treatment Devices

Instrument Family

Medical Device Media Reporting Pioneer

Share Professional Medical Device Knowledge

Focus

Source: Device Home

November 6, 2024, in the morning,Jiangsu TINGSN Technology Co., Ltd. (TINGSN) and GE Healthcare signed a strategic cooperation agreement in Shanghai.TINGSN Chairman Zhang Dongyu, General Manager Wang Jing, Partner Wu Jian, Regulatory Director Xu Yong, GE Healthcare China President and CEO Zhang Yihao, GE Healthcare China Vice President and Advanced Visualization Diagnostic and Therapeutic Business General Manager Chen Chuhui, GE Healthcare China Vice President and Ultrasound Business General Manager Wang Lei, and GE Healthcare Ultrasound Business Cardiac Ultrasound Product Director Wang Jun attended the signing ceremony.

Powerful Combination, Embarking on a New Journey in Ultrasound Development

TINGSN and GE Healthcare have both achieved remarkable success in the ultrasound field.

TINGSN, as a company at the forefront of technological innovation, has demonstrated extraordinary strength and potential in the ultrasound field.TINGSN's self-developed and produced TINGSN Sonic Eyes 10, a disposable intracardiac echocardiography diagnostic catheter, obtained NMPA registration on November 28, 2023. It is an innovative medical device approved by NMPA and also China’s first domestically produced intracardiac echocardiography diagnostic catheter.The product has received widespread attention and recognition in the field of cardiovascular medicine in China after its market launch. Currently, it has been applied in clinical practice by more than 160 hospitals and has been highly praised by clinicians.

As a giant in the global medical industry, GE Healthcare has long been renowned in the field of ultrasound diagnostic technology, with deep technical accumulation and rich practical experience.Vivid iq, as a flagship portable ultrasound diagnostic system from GE, inherits the profound technical foundation of GE Vivid and incorporates more innovative echocardiography technology., with its excellent ergonomic design, powerful cardiac clinical applications, and intelligent operational processes, Vivid iq has gradually assumed an important position in the international medical market, providing precise diagnostic support to countless medical institutions worldwide.

The official signing of this strategic cooperation agreement is based on the profound insights and strategic planning of both parties regarding the development trends in the intracardiac ultrasound field. TINGSN and GE Healthcare will fully leverage their respective strengths.Adapt TINGSN's ICE catheter to GE Healthcare's Vivid iq ultrasound system.In order to rapidly expand the market share of TINGSN's ICE catheter in China, and prepare for TINGSN's ICE to enter the international market, while also broadening the depth and breadth of GE Healthcare's Vivid iq ultrasound diagnostic system applications in the cardiovascular field, further solidifying its leading position in the global medical device market.

The signing of this strategic cooperation agreement not only injects strong momentum into the development of TINGSN and GE Healthcare, but also sets a new benchmark for the global intracardiac ultrasound field. TINGSN will take this strategic cooperation as an important opportunity to move forward hand in hand with GE Healthcare. Through technical complementarity and joint promotion, both parties will further enhance their influence in the global medical field, bring more benefits to patients with heart disease, and push medical technology to a higher level.

Broad application prospects

Intracardiac echocardiography (ICE) combines ultrasound imaging technology with catheter techniques to accurately obtain anatomical structure information of the heart during interventional procedures. It simultaneously displays cardiac hemodynamics, enabling real-time dynamic assessment of local myocardial and overall cardiac function. ICE, as a unique imaging technology, has been clinically proven to be safe and effective. This imaging technique is also expected to become an important component of the standard process for cardiac interventional surgery.

The development and penetration of cardiovascular interventional diagnosis and treatment technologies, as well as the aging population, are inseparable from the advancement of ultrasound imaging technology. Intracardiac echocardiography (ICE) makes complex interventional treatments simpler for operators, with more precise anatomical positioning, shorter operation time, and less radiation exposure. While achieving excellent treatment outcomes, it significantly reduces treatment risks for patients and holds promising application prospects.The strong collaboration between TINGSN and GE Healthcare is worth our continued anticipation.

END

The Medical Section of the CIIE Leaves Nothing Unseen, Johnson & Johnson Medical Tech's Full Range of Surgical Solutions Are Truly Hardcore

Top MR Sales Ranking in County Hospitals Over the Past Three Years

The Father of Taobao Invests in a Medical Device IPO?

A-share Medical Device Leader Sells Off This Business for 634 Million Yuan

Preview of the CIIE: "Black Tech" in Surgical Instruments

Zhangjiang Group Increases Investment in This Ultrasound Research Institute

Stock Price Drops 16%, Philips CEO: China Will Come Back

Preview of CIIE: "Black Technology" in Medical Imaging

Midea Invested, Chinese-Made Surgical Robot Company Canceled

Top 100 Medical Device Companies Build New Headquarters

BusinessBusiness cooperation email: qxzj@landianyiliao.com